Piper Sandler Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price decreased by analysts at Piper Sandler from $855.00 to $854.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price objective would suggest a potential upside of 28.51% from the company’s current price.

A number of other research firms also recently commented on REGN. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $788.00 to $730.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $787.67.

Regeneron Pharmaceuticals Trading Down 0.5%

Shares of REGN stock opened at $664.52 on Thursday. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The business’s fifty day moving average price is $645.30 and its 200 day moving average price is $722.39. The firm has a market capitalization of $70.25 billion, a PE ratio of 16.19, a P/E/G ratio of 1.47 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter last year, the firm posted $8.22 EPS. The business’s revenue was up 19.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.33 EPS for the current fiscal year.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently made changes to their positions in REGN. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $226,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $3,183,000. Gabelli Funds LLC raised its holdings in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after acquiring an additional 55 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in Regeneron Pharmaceuticals by 18.8% during the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after acquiring an additional 5,120 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.